Last reviewed · How we verify
Guanfacine (sustained release)
Guanfacine (sustained release) is a Alpha-2A adrenergic receptor agonist Small molecule drug developed by Neurology Group of Bergen County, P.A.. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.
Guanfacine (sustained release) is a small molecule used to treat Attention-deficit/Hyperactivity Disorder (ADHD). It is administered to improve language-based learning skills in individuals with ADHD.
At a glance
| Generic name | Guanfacine (sustained release) |
|---|---|
| Sponsor | Neurology Group of Bergen County, P.A. |
| Drug class | Alpha-2A adrenergic receptor agonist |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Guanfacine selectively binds to alpha-2A adrenergic receptors in the brain, particularly in the prefrontal cortex, which decreases norepinephrine signaling and enhances working memory and executive function. The sustained-release formulation provides continuous receptor activation over 24 hours, allowing once-daily dosing. This mechanism makes it effective for attention-deficit/hyperactivity disorder (ADHD) and related conditions involving executive dysfunction.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Hypertension
Common side effects
- Somnolence
- Fatigue
- Headache
- Dizziness
- Hypotension
- Bradycardia
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guanfacine (sustained release) CI brief — competitive landscape report
- Guanfacine (sustained release) updates RSS · CI watch RSS
- Neurology Group of Bergen County, P.A. portfolio CI
Frequently asked questions about Guanfacine (sustained release)
What is Guanfacine (sustained release)?
How does Guanfacine (sustained release) work?
What is Guanfacine (sustained release) used for?
Who makes Guanfacine (sustained release)?
What drug class is Guanfacine (sustained release) in?
What development phase is Guanfacine (sustained release) in?
What are the side effects of Guanfacine (sustained release)?
What does Guanfacine (sustained release) target?
Related
- Drug class: All Alpha-2A adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2A adrenergic receptor
- Manufacturer: Neurology Group of Bergen County, P.A. — full pipeline
- Therapeutic area: All drugs in Neurology / Psychiatry
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing